<DOC>
	<DOCNO>NCT02904304</DOCNO>
	<brief_summary>National clinical trial , phase III , multicenter , randomize , prospective , double-blind , parallel , placebo-controlled , one hundred fifty ( 150 ) subject sex age equal 18 year randomly allocate one drug group placebo group .</brief_summary>
	<brief_title>Desloratadine , Phenylephrine Hcl , Ibuprofen Compared Placebo Treatment Symptoms Associated With Common Cold/Flu</brief_title>
	<detailed_description>The investigational product combination desloratadine , phenylephrine hydrochloride ibuprofen . The desloratadine antihistamine selectively block activity histamine receptor-1 ( H1 ) result non sedative prolong antiallergic effect . The phenylephrine potent stimulator postsynaptic α receptor minimal effect β receptor heart . The ibuprofen 's mechanism fully know . It non selective inhibitor cyclooxygenase , enzyme involved prostaglandin synthesis route arachidonic acid . It believe pharmacological effect due inhibition cyclooxygenase-2 ( COX-2 ) , reduce prostaglandin synthesis involve mediation inflammation , pain , fever swell .</detailed_description>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Age old equal 18 young 66 year ; Subjects diagnose common cold / flu syndrome define clinical evaluation presence two follow symptom : sneezing , rhinorrhea , nasal obstruction , headache , throat discomfort , sore throat , dysphonia , myalgia , cough fever classify moderate intense four intensity scale ( 04 ) item ( 0 = absent , 01 = light , 02 = moderate , 03 = severe ) ; Beginning symptom common cold / flulike syndrome minimum period 24 hour maximum 72 hour prior V0 ; Ability understand consent participate clinical research , express signing Informed Consent Form ( ICF ) ; Any laboratorial finding ( clinical evaluation / physical evaluation / vital sign / ECG change ) Investigator consider risk subject study ; Hypersensitivity drug component use study ; Women pregnancy nursing period ; Women reproductive age agree use contraception acceptable [ oral contraceptive , injectable contraceptive , intrauterine device ( IUD ) , hormonal implant , barrier method , hormonal patch tubal ligation ] ; surgically sterile ( bilateral oophorectomy hysterectomy ) , postmenopausal least one ( 01 ) year sexual abstinence ; Subjects participate clinical trial protocol last twelve ( 12 ) month ( National Board Health Resolution 251 07 August 1997 , Part III , subitem J ) , unless investigator considers may direct benefit ; Alcohol abuse , accord investigator , may interfere pharmacological adherence clinical protocol ; Any medical condition may interfere efficacy / safety treatment investigational product , limited disorder describe : Untreated uncontrolled Hyperthyroidism Uncontrolled epilepsy diagnosis glaucoma Moderate severe persistent asthma ( untreated uncontrolled ) NSAIDinduced asthma diagnose Systemic hypertension ( SH ) stage III uncontrolled Moderate severe congestive heart failure Acute myocardial infarction unstable angina Uncontrolled cardiac arrhythmia Liver failure clinical consequence Renal failure clinical consequence Diagnosed HIV positive uncontrolled Diabetes type 1 type 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Flu</keyword>
	<keyword>Treatment</keyword>
</DOC>